Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 397-402

  Carraro, Silvia ^a,f   Roca, Enrique L ^a,b   Cartelli, Cristina ^c   Rafailovici, Luisa ^d   Castillo Odena, Socorro ^e   Wasserman, Ernesto ^a,b   Gualdrini, Ubaldo ^a   Huertas, Eduardo ^b   Barugel, Mario ^a   Ballarino, Graciela ^a,b,c,d,e   Rodriguez, María C ^a,b,c,d,e   Masciangioli, Guillermo ^a  

^a HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^b INSTITUTO ALEXANDER FLEMING   (Argentina)

^c Asociación de Lucha Contra El Cáncer   (Argentina)

^d Vidt Centro Medico   (Argentina)

^e Hospital Escuela   (Argentina)

^f NONE   (Argentina)

Author keywords

Chemoradiotherapy; Oxaliplatin; Rectal cancer

Indexed keywords

CHEMOTHERAPY; DRUG INFUSION; PATIENT TREATMENT; TOXICITY; TUMORS;

PRECLINICAL SYNERGY;

RADIOTHERAPY;

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; SEPSIS; SKIN TOXICITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECTAL NEOPLASMS;

EID: 0036803131     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02933-4     Document Type: Article

References (19)

1. Buls J.G. Commentary on decision making. Blake C., Surgical oncology clinics of North America. 2000;851-852 WB Saunders.
2. Moertel C.G. Natural history of gastrointestinal cancer. Moertel C.G., Reitmeier R.J., Advanced gastrointestinal cancer Clinical management and chemotherapy . 1969;3-14 Harper & Row, New York, NY.
3. Nelson H. Surgical approaches to the management of locally advanced primary or recurrent rectal cancer. Thirty-fourth Annual Meeting ASCO Educational Book. 1998;440-444.
4. Glimelius B. Chemoradiotherapy for rectal cancer - is there an optimal combination? Ann Oncol. 12:2001;1039-1045.
5. de Gramont A., Figer M., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2000;2938-2947.
6. Grothey A., Deschler B., Kroening H., et al. Bolus 5-fluorouracil/folinic acid (Mayo) vs. weekly high dose 24 h 5-fluorouracil infusion/leucovorin + oxaliplatin in advanced colorectal cancer. Results of a phase III study. (Abstr.) Proc Am Soc Clin Oncol. 20:2001;125a.
7. Roca E., Montiel M., Barugel M., et al. 5-FU and leucovorin (Mayo regimen) plus bi-monthly oxaliplatin in patients with advanced colorectal cancer. (Abstr.) Proc Am Soc Clin Oncol. 18:1999;298a.
8. Van Kooten M., Batagejl E., Cavarra G., et al. Expanded Access Program (EAP) polichemotherapy 5 fluorouracil (FU) + leucovorin (FA) + oxaliplatin (OX) in fluoropyrimidine resistant advanced colorectal (FRAC) cancer patients (PTS) Preliminary report . (Abstr.) Proc Am Soc Clin Oncol. 17:1998;272a.
9. Freyer G., Bossard N., Romestaing P., et al. Addition of oxaliplatin to continuous fluorouracil, L-Folinic acid, and concomitant radiotherapy in rectal cancer The Lyon R-97-03 phase I trial . J Clin Oncol. 19:2001;2433-2438.
10. st Annual Meeting Am. Assoc. Cancer Res. (AACR).
11. Moertel C.G., Gunderson L.L., Maillard J.A., et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol. 12:1994;21-27.
12. Kaplan E.L., Meier E. Nonparametric estimation for incomplete observation. J Am Stat Assoc. 53:1958;457-481.
13. Caussanel J.P., Leví F., Brienza S., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 82:1990;1046-1050.
14. Willett C.G., Haller D., Steele G. Controversies in the management of localized rectal cancer. 1999;212-221. Thirty-fifth Annual Meeting ASCO Educational Book.
15. Milano C., Roca E., Wasserman E., et al. Resectable rectal cancer Preoperative radio-chemotherapy including cisplatin . (Abstr.) Proc Am Soc Clin Oncol. 14:1995;213.
16. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer The Lyon R90-01 randomized trial . J Clin Oncol. 17:1999;2396-2402.
17. Minsky B.D., Cohen A.M., Kemeny N., et al. The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer. 71:1993;3486-3492.
18. Rich T.A., Skibber J.M., Ajani J.A., et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 32:1995;1025-1029.
19. Metzger U. Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. Eur J Cancer. 26:1990;753-755.